FDA Clearance Tracker · P180035-S031
MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
Last checked: Nov 20, 2026Latest source record: Oct 28, 2025 (this decision)Source: openFDAMethods & limitations
Decided
Oct 28, 2025
Approved
Time to decision
62 days
Received Aug 27, 2025. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P180035-S031
- Device name
- MiSight 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear
- Applicant
- CooperVision, Inc.
- Applicant location
- Pleasanton, CA
- Received
- Aug 27, 2025
- Decided
- Oct 28, 2025
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P180035
Device type
- Device class
- Class III
- Specialty
- Ophthalmology
FDA's approval statement
As written in FDA's record.
Approval of protocol changes to enroll approximately 1000 subjects in PAS002 to achieve at least 4000 patient years total (approximately 2000 per study) with an average follow up of 2-3 years per subject. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P180035.
Source documents
Other decisions for CooperVision, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K234127 · Decided Jan 25, 2024 · 28 days after receipt
Device type: Lenses, Soft Contact, Daily Wear (LPL) · Ophthalmology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.